We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 10, 2022

Clinical Outcomes of Icotinib-Treated Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by ctDNA Testing

JAMA Oncology

 

Additional Info

JAMA Oncology
Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial
JAMA Oncol 2022 Jul 21;[EPub Ahead of Print], J Xu, Z Liu, H Bai, G Dong, J Zhong, R Wan, A Zang, X Li, Q Li, J Guo, N Du, D Zhong, Y Huang, Q Lv, J Zhang, Y Zhao, L Gao, L Li, C Zhang, J Zhao, B Li, Z Liu, Z Yang, D Ji, T Wang, J Duan, Z Wang, J Wang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading